ProCE Banner Activity

IAS 2017 Data Shed Light on the Potential Use of Investigational ART Coformulations

Clinical Thought
How do phase III data on bictegravir and doravirine affect the potential future HIV treatment landscape? Here’s my take.

Released: September 11, 2017

Expiration: September 10, 2018

No longer available for credit.

Share

Faculty

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

ViiV Healthcare

Faculty Disclosure

Primary Author

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV and funds for research support from Abbott, Gilead Sciences, and Merck.